The molecular combinations involved in creating new treatments are vast, so Nvidia is customizing its technology to address ...

In a university lab, an AI system generated millions of novel molecules to fight drug-resistant infections. And they're ...

A new compound, called VU319, has delivered promising results in a Phase 1 trial for treating Alzheimer’s disease and other neudegenerative conditions. The corresponding study was published in ACS ...

Wockhardt’s stock price fell 93% from Rs 2,169 in March 2013 to Rs 145 by March 2023. Yet even in this period, Khorakiwala ...

Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platformSAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced ...

Several European biotechs, including Cellbox Labs, Evotec SE, Nanolive SA, and Salipro Biotech AB, have developed innovative ...

Dosing of first MAD cohort in Phase 1 trial of O3R-5671 complete with no drug related adverse events Pharmacokinetic profile demonstrates long ...

Today, Novo Nordisk released topline results from their phase 3 Evoke and Evoke+ trials of semaglutide, an oral GLP-1 drug, in individuals with early-stage Alzheimer's disease, showing the trials did ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Pharmaceuticals announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology ...